13 kinds of compound vitamin injection, a new chemical drug of 3.2 category of Hisilicon, will enter the on-site inspection this month, and will become the first imitation after being approved

According to the information on the website of CFDA, 13 kinds of compound vitamin injection, a new chemical drug of 3.2 category of HISCO (002653 SZ), will enter the drug registration and production site for inspection this month, and it is expected to be approved for production within half a year according to the drug review process 13 kinds of multivitamin injection are the key reserve varieties of Hisilicon, which are expected to become the first domestic imitations after being approved 13 kinds of compound vitamin injection belong to parenteral nutrition According to IMS data statistics, in recent years, the annual growth rate of clinical nutrition market has remained at about 18% At present, the scale of domestic clinical nutrition market has reached 7 billion yuan, of which more than 80% are parenteral nutrition drugs, reaching 6 billion yuan According to relevant data, the number of inpatients in China exceeds 130 million, of which 40% are at risk of nutrition, but less than 10% get corresponding treatment, so there is a large space for improvement According to the data on CFDA website, at present, there are no domestic enterprises that have obtained the production approval documents of 13 kinds of compound vitamin injection, and only hisilico has applied for the production approval documents, which is expected to be the first one in China after being approved It is worth mentioning that this is the second time that HISCO has applied for the production of 13 kinds of compound vitamin injection, and whether the product was approved at the level of Drug Evaluation Center (CDE) of State Food and Drug Administration in 2012 Previously, people of the company told DZH news that 13 kinds of multivitamin injection are the company's key reserve varieties, and the company will actively strive for approval, not excluding the application for review and other procedures Hisic is mainly engaged in the production and sales of chemical pharmaceutical preparations and APIs Parenteral nutrition medicine is the main research and development field of hisic At present, the company has a series of main products such as invert sugar injection, fat soluble vitamins for injection, etc Published by: Ding Yingying / Gu Meiyi reviewed by: Kang Yiyao / Xu Xueli * the information in this article is for reference only, and the investors shall bear the operational risk accordingly (official wechat interactive DZH News Shanghai station Tel.: + 86-21-2021 9988-31124 Beijing station Tel.: + 86-10-5799 5701 weibo.com/dzhnews) for more stock news, please log in to wisdom 365.